MoonLake Immunotherapeutics

NasdaqCM MLTX

MoonLake Immunotherapeutics Free Cash Flow Yield on December 30, 2024: -2.43%

MoonLake Immunotherapeutics Free Cash Flow Yield is -2.43% on December 30, 2024, a -103.95% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

MoonLake Immunotherapeutics 52-week high Free Cash Flow Yield is -1.07% on February 12, 2024, which is 55.71% above the current Free Cash Flow Yield.
MoonLake Immunotherapeutics 52-week low Free Cash Flow Yield is -2.78% on October 24, 2024, which is -14.80% below the current Free Cash Flow Yield.
MoonLake Immunotherapeutics average Free Cash Flow Yield for the last 52 weeks is -2.01%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: MLTX

MoonLake Immunotherapeutics

CEO	Dr. Jorge Santos da Silva
IPO Date	Oct. 20, 2020
Location	Switzerland
Headquarters	Dorfstrasse 29
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Key trends

Past 5 years